JP2014076062A5 - - Google Patents

Download PDF

Info

Publication number
JP2014076062A5
JP2014076062A5 JP2013268626A JP2013268626A JP2014076062A5 JP 2014076062 A5 JP2014076062 A5 JP 2014076062A5 JP 2013268626 A JP2013268626 A JP 2013268626A JP 2013268626 A JP2013268626 A JP 2013268626A JP 2014076062 A5 JP2014076062 A5 JP 2014076062A5
Authority
JP
Japan
Prior art keywords
antibody
seq
heavy chain
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013268626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014076062A (ja
JP5933517B2 (ja
Filing date
Publication date
Priority claimed from PCT/AU2011/000155 external-priority patent/WO2011100786A1/en
Application filed filed Critical
Publication of JP2014076062A publication Critical patent/JP2014076062A/ja
Publication of JP2014076062A5 publication Critical patent/JP2014076062A5/ja
Application granted granted Critical
Publication of JP5933517B2 publication Critical patent/JP5933517B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013268626A 2010-08-17 2013-12-26 ヒト化抗インターロイキン３レセプターα鎖抗体 Active JP5933517B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37448910P 2010-08-17 2010-08-17
US61/374,489 2010-08-17
AUPCT/AU2011/000155 2011-02-17
PCT/AU2011/000155 WO2011100786A1 (en) 2010-02-17 2011-02-17 Compositions and methods for targeting type 1 interferon producing cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013524306A Division JP5524418B2 (ja) 2010-08-17 2011-08-17 ヒト化抗インターロイキン３レセプターα鎖抗体

Publications (3)

Publication Number Publication Date
JP2014076062A JP2014076062A (ja) 2014-05-01
JP2014076062A5 true JP2014076062A5 (enExample) 2014-09-18
JP5933517B2 JP5933517B2 (ja) 2016-06-08

Family

ID=45604615

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013524306A Active JP5524418B2 (ja) 2010-08-17 2011-08-17 ヒト化抗インターロイキン３レセプターα鎖抗体
JP2013268626A Active JP5933517B2 (ja) 2010-08-17 2013-12-26 ヒト化抗インターロイキン３レセプターα鎖抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013524306A Active JP5524418B2 (ja) 2010-08-17 2011-08-17 ヒト化抗インターロイキン３レセプターα鎖抗体

Country Status (13)

Country Link
US (3) US8569461B2 (enExample)
EP (2) EP2606069B1 (enExample)
JP (2) JP5524418B2 (enExample)
KR (1) KR101347688B1 (enExample)
CN (1) CN103025761B (enExample)
CA (1) CA2805176C (enExample)
DK (1) DK2606069T3 (enExample)
ES (1) ES2506340T3 (enExample)
GB (1) GB2488091B (enExample)
IL (1) IL225631A (enExample)
NZ (1) NZ604510A (enExample)
PL (1) PL2606069T3 (enExample)
WO (1) WO2012021934A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2305300T3 (en) * 2008-07-10 2016-06-06 Toray Industries Pharmaceutical composition for treatment and prevention of cancer
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
PL2426148T3 (pl) 2009-04-27 2016-01-29 Kyowa Hakko Kirin Co Ltd Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
EP4053162A1 (en) * 2012-05-18 2022-09-07 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
WO2014138819A1 (en) * 2013-03-14 2014-09-18 Csl Limited Agents that neutralize il-3 signaling and uses thereof
US20160031996A1 (en) * 2013-03-14 2016-02-04 Csl Limited Anti il-3r alpha agents and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
TN2018000324A1 (en) * 2015-01-23 2020-01-16 Sanofi Sa ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
CN107921146A (zh) * 2015-06-23 2018-04-17 拜耳医药股份有限公司 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc)
LT3313884T (lt) * 2015-06-29 2021-03-10 Immunogen, Inc. Anti-cd123 antikūnai, konjugatai ir jų dariniai
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
CN109310781B (zh) * 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
JP7224289B2 (ja) 2016-09-21 2023-02-17 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US11660351B2 (en) 2016-12-21 2023-05-30 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
TWI757499B (zh) 2017-06-02 2022-03-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
CA3089754A1 (en) 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN119954959A (zh) * 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
EP3966242A1 (en) 2019-05-04 2022-03-16 Inhibrx, Inc. Cd123-binding polypeptides and uses thereof
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
KR20230084508A (ko) 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
AU2022323756A1 (en) * 2021-08-06 2023-12-14 Cimeio Therapeutics Ag Discernible cell surface protein variants for use in cell therapy
AU2023274452A1 (en) 2022-05-27 2025-01-16 Innate Pharma Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
EP4296280A1 (en) 2022-06-21 2023-12-27 F. Hoffmann-La Roche AG Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs)
EP4619044A1 (en) 2022-11-17 2025-09-24 Hans-Georg Lerchen Antibody-drug-conjugates cleavable in a tumor microenvironment

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1997024373A1 (en) * 1995-12-29 1997-07-10 Medvet Science Pty. Limited Monoclonal antibody antagonists to haemopoietic growth factors
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
KR20010043323A (ko) 1998-05-06 2001-05-25 제넨테크, 인크. 이온 교환 크로마토그래피에 의한 단백질 정제 방법
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
KR100627856B1 (ko) * 2004-06-28 2006-09-25 에스케이 텔레콤주식회사 착신측 교환기를 이용하여 멀티미디어 링백톤 서비스를제공하는 방법 및 시스템
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
CN101098890B (zh) * 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
AU2006210724A1 (en) 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
KR20080068004A (ko) 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
EP2064240A2 (en) 2006-09-18 2009-06-03 Xencor, Inc. Optimized antibodies that target hm1.24
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
AU2008331436A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells
WO2010036856A2 (en) * 2008-09-26 2010-04-01 Wyeth Llc Compatible display vector systems
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
PL2426148T3 (pl) * 2009-04-27 2016-01-29 Kyowa Hakko Kirin Co Ltd Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2014076062A5 (enExample)
JP2013537418A5 (enExample)
US12448423B2 (en) Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains
CN107580500B (zh) 抗pvrig抗体和使用方法
JP2020513786A5 (enExample)
JP2016538830A5 (enExample)
US12029778B2 (en) Interleukin-18 mimics and methods of use
JP2009521909A5 (enExample)
JP2017529838A5 (enExample)
JP2013165711A5 (enExample)
JP2009502171A5 (enExample)
JP2018500014A5 (enExample)
JP2011514150A5 (enExample)
JP2019536806A5 (enExample)
JP2014511179A5 (enExample)
JP2008542278A5 (enExample)
JP2015517470A5 (enExample)
JP2015535691A5 (enExample)
JP2016506388A5 (enExample)
AU2020283817A1 (en) TIGIT and PD-1/TIGIT-binding molecules
JP2017531427A5 (enExample)
JP2014158469A5 (enExample)
JP2020527332A5 (enExample)
MX2014008101A (es) Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
JP2015506945A5 (enExample)